Acromegaly: a Latin American perspective

Mercado, Moisés

doi:10.1007/s11102-013-0518-9

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of acromegaly/gigantism has advenced greatly in recent decades, and studies indicate that the strict control of GH/IGF-1 levels reduces morbidity and mortality 5,10,11. The subjects in the present study reflect this evolution.…”

Section: Discussionmentioning

confidence: 79%

“…Treatment of acromegaly is considered effective when patients achieve basal plasma GH levels below 1 ng/mL or glucose-suppressed GH levels below 0.4 ng/mL and normal IGF-1 levels 5-7. Currently, these hormonal control targets can only be achieved by following a treatment plan consisting of tumor ablation either preceded or followed by pharmacological treatment with increasing individualized doses of somatostatin receptor ligands (SRLs) and, in some cases, dopamine receptor agonists and GH receptor antagonists 4,8-10.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

Borges¹,

Lara²,

Tomé³

et al. 2017

Clinics

View full text Add to dashboard Cite

OBJECTIVE:To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro.METHODS:Cross-sectional and retrospective study of thirty cases treated over a period of two decades.RESULTS:17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels.CONCLUSION:The current treatment options enable patients seen in regional reference centers to achieve strict control parameters, which allows them to be treated close to their homes.

show abstract

Section: Discussionmentioning

confidence: 79%